K
Kok Ann Gwee
Researcher at National University of Singapore
Publications - 50
Citations - 3292
Kok Ann Gwee is an academic researcher from National University of Singapore. The author has contributed to research in topics: Irritable bowel syndrome & Medicine. The author has an hindex of 21, co-authored 39 publications receiving 2875 citations. Previous affiliations of Kok Ann Gwee include Cork University Hospital & Gleneagles Hospital.
Papers
More filters
Journal ArticleDOI
Design of Treatment Trials for Functional Gastrointestinal Disorders.
E. Jan Irvine,E. Jan Irvine,Jan Tack,Michael D. Crowell,Kok Ann Gwee,Meiyun Ke,Max Schmulson,William E. Whitehead,Brennan Spiegel +8 more
TL;DR: This article summarizes recent progress and regulatory guidance on design of trials to assess the efficacy of new therapies for functional gastrointestinal disorders (FGIDs).
Journal ArticleDOI
Increased rectal mucosal expression of interleukin 1β in recently acquired post-infectious irritable bowel syndrome
Kok Ann Gwee,Stephen M. Collins,Nicholas W. Read,Andrea Rajnakova,Deng Y,J.C. Graham,M.W. McKendrick,Shabbir Moochhala +7 more
TL;DR: It is indicated that those patients who develop IBS post infection exhibit greater IL-1β mRNA expression, both during and after the infection, compared with individuals who do not develop PI-IBS.
Journal ArticleDOI
The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review
Ami D. Sperber,Dan L. Dumitrascu,Shin Fukudo,Charles D. Gerson,Uday C Ghoshal,Kok Ann Gwee,A Pali S Hungin,J Y Kang,Chen Minhu,Max Schmulson,Arkady Bolotin,Michael Friger,Tamar Freud,William E. Whitehead +13 more
TL;DR: It is concluded that publication of a single pooled global prevalence rate, which is easily calculated, would not be appropriate or contributory, and future studies should focus on regional and cross-cultural differences that are more likely to shed light on pathophysiology.
Journal ArticleDOI
An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome
John Kellow,Oh-Young Lee,Full Young Chang,S. Thongsawat,M. Z. Mazlam,H. Yuen,Kok Ann Gwee,Young-Tae Bak,J. Jones,A. Wagner +9 more
TL;DR: Tegaserod 6 mg twice daily is an effective, safe, and well tolerated treatment for patients in the Asia-Pacific region suffering from IBS and whose main bowel symptom is not diarrhoea.
Journal ArticleDOI
Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study
TL;DR: The findings suggest that the beneficial effects of melatonin on abdominal pain in IBS patients with sleep disturbances are independent of its action on sleep disturbances or psychological profiles.